« Back
Home /
diABZI STING agonist-1 (trihydrochloride)

diABZI STING agonist-1 (trihydrochloride)

Item no.	HY-112921B-10mg
Manufacturer	MedChem Express
CASRN	2138299-34-8
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 1 mg 250 mg 25 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Nov 7. ACS Infect Dis. 2022 Mar 11;8(3):463-471. Adv Sci (Weinh). 2025 Apr;12(14):e2417686. Am J Cancer Res. 2023 May 15;13(5):2055-2065. bioRxiv. 2025 Feb 27:2025.02.21.639458. bioRxiv. 2025 Jul 18:2025.07.14.664814. bioRxiv. 2025 Nov 18. Cancer Lett. 2022 Oct 28:547:215885. Cancer Lett. 2024 Jun 21:217081. Cell Death Dis. 2022 Jul 28;13(7):653. Cell Immunol. 2021 Aug:366:104384. EMBO J. 2025 Jan;44(1):141-165. Exp Hematol Oncol. 2024 Aug 5;13(1):77. Front Immunol. 2020 Jul 8:11:1430. Front Pharmacol. 2023 Apr 4:14:1160445. J Bone Miner Res. 2024 Jun 14:zjae093. J Ethnopharmacol. 2024 Aug 17:118661. J Invest Dermatol. 2022 Apr;142(4):1158-1170.e8. Mol Cell. 2023 May 4;83(9):1502-1518.e10. Nat Nanotechnol. 2021 Nov;16(11):1260-1270. OncoImmunology. 2022 Feb 1;11(1):2030021. PLoS One. 2021 Oct 27;16(10):e0258989. Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120. Protein Cell. 2022 Apr;13(4):281-301. Sci China Life Sci. 2024 Dec;67(12):2664-2677. Sci Rep. 2022 Oct 24;12(1):17827. Thorac Cancer. 2022 May; 13(9): 1361–1368. World J Tradit Chin Med. 2025 April 17. World J Tradit Chin Med. 2025 Oct 28. Adv Sci (Weinh). 2024 Nov 19:e2407222. Biomed Pharmacother. 2024 Feb:171:116007. Cancer Lett. 2024 May 1:589:216836. Cell Death Differ. 2024 Jan;31(1):78-89. Cell Death Differ. 2025 Jun;32(6):1167-1179. Cell Rep. 2025 Nov 18;44(12):116581. Chin Herb Med. 2024 Apr 30;16(3):422-434. Chin Herb Med. 2025 Jan 7. Chin Med. 2024 Aug 15;19(1):107. FASEB J. 2025 Apr 15;39(7):e70530. Genes Dis. 2023 Sep 2;11(6):101074. Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):13. J Exp Med. 2021 Feb 1;218(2):e20200887. University of California San Diego. 2023
Smiles	O=C(C1=CC(C)=NN1CC)NC2=NC3=CC(C(N)=O)=CC(OC)=C3N2C/C=C/CN4C5=C(OCCCN6CCOCC6)C=C(C(N)=O)C=C5N=C4NC(C7=CC(C)=NN7CC)=O.Cl.Cl.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2138299-34-8
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds
Manufacturer - Targets	STING
Manufacturer - HS Code	H302, H315, H319
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	959.32
Product Description	diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO : 90 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	No Development Reported
UNSPSC Code	12352005
Precautionary	H302, H315, H319

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.